 Virginia Borges
Concepts (552)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 133 | 2024 | 2104 | 12.230 |
Why?
| | Pregnancy Complications, Neoplastic | 14 | 2021 | 52 | 3.070 |
Why?
| | Postpartum Period | 19 | 2024 | 331 | 2.810 |
Why?
| | Receptor, ErbB-2 | 28 | 2023 | 325 | 2.290 |
Why?
| | Cancer Survivors | 17 | 2024 | 257 | 2.250 |
Why?
| | Receptors, Estrogen | 19 | 2021 | 422 | 2.010 |
Why?
| | Carcinoma, Ductal, Breast | 10 | 2023 | 80 | 1.810 |
Why?
| | Mastectomy | 17 | 2024 | 132 | 1.760 |
Why?
| | Antineoplastic Agents, Hormonal | 12 | 2024 | 155 | 1.750 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 18 | 2023 | 1560 | 1.400 |
Why?
| | Lactation | 9 | 2021 | 175 | 1.320 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 7 | 2023 | 54 | 1.180 |
Why?
| | Female | 149 | 2024 | 68829 | 1.150 |
Why?
| | Breast | 10 | 2021 | 140 | 1.070 |
Why?
| | Antineoplastic Agents | 12 | 2023 | 2045 | 1.000 |
Why?
| | Neoplasm Metastasis | 10 | 2020 | 610 | 0.980 |
Why?
| | Trastuzumab | 13 | 2023 | 100 | 0.960 |
Why?
| | Protein Kinase Inhibitors | 6 | 2021 | 886 | 0.930 |
Why?
| | Receptors, Progesterone | 6 | 2021 | 341 | 0.900 |
Why?
| | Adult | 86 | 2024 | 35634 | 0.890 |
Why?
| | Pregnancy | 32 | 2024 | 6423 | 0.880 |
Why?
| | Mammary Glands, Human | 7 | 2020 | 63 | 0.880 |
Why?
| | Humans | 158 | 2024 | 129847 | 0.850 |
Why?
| | Triple Negative Breast Neoplasms | 6 | 2020 | 193 | 0.820 |
Why?
| | Supreme Court Decisions | 1 | 2022 | 11 | 0.790 |
Why?
| | Mammary Glands, Animal | 9 | 2021 | 128 | 0.740 |
Why?
| | BRCA2 Protein | 5 | 2024 | 54 | 0.720 |
Why?
| | Carcinoma | 3 | 2021 | 213 | 0.720 |
Why?
| | Brain Neoplasms | 9 | 2023 | 1149 | 0.710 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2020 | 35 | 0.700 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2022 | 753 | 0.670 |
Why?
| | Neoadjuvant Therapy | 6 | 2021 | 379 | 0.650 |
Why?
| | Maternal Age | 1 | 2020 | 125 | 0.650 |
Why?
| | Fertility Preservation | 6 | 2024 | 39 | 0.640 |
Why?
| | Estradiol | 5 | 2019 | 494 | 0.610 |
Why?
| | Extracellular Vesicles | 1 | 2020 | 129 | 0.600 |
Why?
| | Prospective Studies | 31 | 2024 | 7158 | 0.590 |
Why?
| | Prognosis | 15 | 2022 | 3773 | 0.580 |
Why?
| | Neoplasm Recurrence, Local | 13 | 2023 | 957 | 0.580 |
Why?
| | Young Adult | 37 | 2024 | 12467 | 0.580 |
Why?
| | Carcinoma in Situ | 3 | 2022 | 44 | 0.570 |
Why?
| | Parity | 7 | 2022 | 121 | 0.560 |
Why?
| | Lymphatic Metastasis | 10 | 2021 | 320 | 0.550 |
Why?
| | Middle Aged | 51 | 2024 | 31177 | 0.550 |
Why?
| | Neoplasm Staging | 17 | 2022 | 1282 | 0.540 |
Why?
| | Neoplasms, Second Primary | 3 | 2024 | 106 | 0.530 |
Why?
| | Quality of Life | 11 | 2024 | 2695 | 0.530 |
Why?
| | Cyclooxygenase 2 | 5 | 2020 | 176 | 0.490 |
Why?
| | Liver Neoplasms | 4 | 2016 | 636 | 0.480 |
Why?
| | Semaphorins | 3 | 2020 | 28 | 0.470 |
Why?
| | Breast Feeding | 5 | 2024 | 424 | 0.470 |
Why?
| | Chemotherapy, Adjuvant | 13 | 2024 | 377 | 0.460 |
Why?
| | Aromatase Inhibitors | 6 | 2019 | 51 | 0.450 |
Why?
| | Antigens, CD | 5 | 2020 | 487 | 0.450 |
Why?
| | Capecitabine | 5 | 2023 | 45 | 0.450 |
Why?
| | Carcinoma, Lobular | 2 | 2012 | 47 | 0.440 |
Why?
| | Melanoma | 4 | 2018 | 730 | 0.440 |
Why?
| | Oxazoles | 4 | 2021 | 30 | 0.440 |
Why?
| | Mutation | 10 | 2023 | 3706 | 0.440 |
Why?
| | Mastectomy, Segmental | 6 | 2022 | 86 | 0.440 |
Why?
| | Skin Neoplasms | 4 | 2013 | 830 | 0.430 |
Why?
| | Combined Modality Therapy | 10 | 2023 | 1201 | 0.420 |
Why?
| | Puerperal Disorders | 2 | 2014 | 31 | 0.420 |
Why?
| | BRCA1 Protein | 4 | 2024 | 65 | 0.410 |
Why?
| | Quinazolines | 4 | 2021 | 243 | 0.390 |
Why?
| | Stromal Cells | 3 | 2013 | 106 | 0.390 |
Why?
| | Biomarkers, Tumor | 10 | 2023 | 1161 | 0.380 |
Why?
| | Anxiety | 7 | 2022 | 976 | 0.380 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2021 | 503 | 0.380 |
Why?
| | Sexual Partners | 3 | 2022 | 185 | 0.350 |
Why?
| | Epithelial Cells | 6 | 2018 | 1063 | 0.350 |
Why?
| | Nevus, Pigmented | 1 | 2011 | 32 | 0.350 |
Why?
| | Disease-Free Survival | 7 | 2023 | 647 | 0.340 |
Why?
| | Neoplasm Invasiveness | 6 | 2020 | 484 | 0.340 |
Why?
| | Pyridines | 4 | 2021 | 478 | 0.340 |
Why?
| | Radiosurgery | 3 | 2021 | 321 | 0.340 |
Why?
| | Tamoxifen | 7 | 2021 | 197 | 0.330 |
Why?
| | Estrogens | 4 | 2015 | 348 | 0.330 |
Why?
| | Cyclophosphamide | 5 | 2020 | 234 | 0.320 |
Why?
| | Adjuvants, Immunologic | 2 | 2022 | 222 | 0.320 |
Why?
| | Risk Factors | 17 | 2024 | 9801 | 0.320 |
Why?
| | Gene Expression Profiling | 8 | 2020 | 1686 | 0.310 |
Why?
| | Thrombophilia | 1 | 2009 | 81 | 0.310 |
Why?
| | T-Lymphocytes | 6 | 2018 | 1937 | 0.300 |
Why?
| | Incidence | 7 | 2024 | 2646 | 0.300 |
Why?
| | Neoplasms | 6 | 2022 | 2454 | 0.300 |
Why?
| | Doxorubicin | 5 | 2020 | 329 | 0.300 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2021 | 1327 | 0.290 |
Why?
| | Animals | 30 | 2021 | 35409 | 0.280 |
Why?
| | Breast Neoplasms, Male | 2 | 2018 | 28 | 0.280 |
Why?
| | Employment | 2 | 2019 | 167 | 0.280 |
Why?
| | Mice | 20 | 2021 | 16983 | 0.280 |
Why?
| | Kaplan-Meier Estimate | 4 | 2020 | 851 | 0.280 |
Why?
| | Fertility | 4 | 2022 | 156 | 0.280 |
Why?
| | Cohort Studies | 11 | 2024 | 5444 | 0.280 |
Why?
| | Decision Making | 4 | 2022 | 864 | 0.280 |
Why?
| | Cell Line, Tumor | 9 | 2020 | 3185 | 0.260 |
Why?
| | Myeloid-Derived Suppressor Cells | 2 | 2018 | 64 | 0.260 |
Why?
| | Maytansine | 2 | 2018 | 16 | 0.260 |
Why?
| | Adaptation, Psychological | 2 | 2022 | 618 | 0.260 |
Why?
| | Time Factors | 7 | 2020 | 6550 | 0.260 |
Why?
| | Disease Management | 3 | 2021 | 592 | 0.250 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2011 | 577 | 0.250 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2023 | 855 | 0.240 |
Why?
| | GPI-Linked Proteins | 3 | 2020 | 68 | 0.240 |
Why?
| | Reproductive History | 2 | 2015 | 18 | 0.240 |
Why?
| | Macrophages | 4 | 2018 | 1489 | 0.240 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 2 | 2022 | 81 | 0.230 |
Why?
| | Proportional Hazards Models | 2 | 2022 | 1199 | 0.230 |
Why?
| | Dimethyl Sulfoxide | 1 | 2005 | 41 | 0.230 |
Why?
| | Adolescent | 20 | 2024 | 20451 | 0.230 |
Why?
| | Genetic Predisposition to Disease | 6 | 2024 | 2271 | 0.230 |
Why?
| | Disease Progression | 10 | 2020 | 2628 | 0.220 |
Why?
| | Bupropion | 1 | 2004 | 40 | 0.220 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 180 | 0.220 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2024 | 35 | 0.220 |
Why?
| | Lymph Nodes | 3 | 2019 | 471 | 0.220 |
Why?
| | Premenopause | 4 | 2021 | 120 | 0.210 |
Why?
| | Aged | 24 | 2023 | 22107 | 0.210 |
Why?
| | Disease Models, Animal | 5 | 2020 | 4077 | 0.210 |
Why?
| | Drug Administration Schedule | 3 | 2018 | 766 | 0.210 |
Why?
| | Diarrhea | 3 | 2019 | 181 | 0.210 |
Why?
| | Estrogen Receptor alpha | 2 | 2021 | 130 | 0.210 |
Why?
| | Liver | 3 | 2020 | 1839 | 0.210 |
Why?
| | Cell Proliferation | 5 | 2021 | 2378 | 0.200 |
Why?
| | Multiple Sclerosis | 1 | 2008 | 438 | 0.200 |
Why?
| | Age Factors | 9 | 2021 | 3161 | 0.200 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2023 | 67 | 0.200 |
Why?
| | Pharmaceutical Preparations | 1 | 2005 | 171 | 0.200 |
Why?
| | Aurora Kinase A | 2 | 2019 | 53 | 0.190 |
Why?
| | Genomic Instability | 1 | 2022 | 48 | 0.190 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2019 | 181 | 0.190 |
Why?
| | Chromatography, Liquid | 1 | 2004 | 426 | 0.190 |
Why?
| | Proteomics | 2 | 2020 | 1058 | 0.190 |
Why?
| | Pilonidal Sinus | 1 | 2001 | 2 | 0.190 |
Why?
| | Condylomata Acuminata | 1 | 2001 | 7 | 0.190 |
Why?
| | Women's Health | 1 | 2024 | 364 | 0.190 |
Why?
| | Hematopoiesis | 1 | 2022 | 184 | 0.190 |
Why?
| | Nausea | 2 | 2018 | 111 | 0.180 |
Why?
| | Ki-67 Antigen | 2 | 2019 | 108 | 0.180 |
Why?
| | Dyspareunia | 1 | 2020 | 8 | 0.170 |
Why?
| | Mass Spectrometry | 1 | 2004 | 717 | 0.170 |
Why?
| | Cancer Care Facilities | 1 | 2020 | 32 | 0.170 |
Why?
| | Body Image | 3 | 2020 | 84 | 0.170 |
Why?
| | Tumor Microenvironment | 6 | 2021 | 627 | 0.170 |
Why?
| | Mice, Inbred BALB C | 6 | 2019 | 1248 | 0.170 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 1050 | 0.170 |
Why?
| | Antibodies, Monoclonal, Humanized | 6 | 2021 | 756 | 0.170 |
Why?
| | Ibuprofen | 2 | 2018 | 81 | 0.170 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2020 | 14 | 0.170 |
Why?
| | Resistance Training | 1 | 2022 | 151 | 0.170 |
Why?
| | Neoplasm Grading | 5 | 2021 | 283 | 0.170 |
Why?
| | Biopsy | 4 | 2018 | 1089 | 0.170 |
Why?
| | Risk | 3 | 2013 | 860 | 0.170 |
Why?
| | Benzodiazepines | 1 | 2021 | 137 | 0.160 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 587 | 0.160 |
Why?
| | Bone Neoplasms | 2 | 2016 | 229 | 0.160 |
Why?
| | Fatigue | 2 | 2018 | 319 | 0.160 |
Why?
| | p21-Activated Kinases | 1 | 2019 | 15 | 0.160 |
Why?
| | Sexual Health | 1 | 2020 | 53 | 0.160 |
Why?
| | Pyrazoles | 3 | 2018 | 403 | 0.160 |
Why?
| | Cell Adhesion | 1 | 2020 | 455 | 0.160 |
Why?
| | Receptor, trkB | 1 | 2019 | 30 | 0.150 |
Why?
| | Social Support | 3 | 2022 | 587 | 0.150 |
Why?
| | Immunohistochemistry | 8 | 2019 | 1690 | 0.150 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2019 | 34 | 0.150 |
Why?
| | Cell Communication | 1 | 2020 | 301 | 0.150 |
Why?
| | Carcinoma, Ductal | 2 | 2011 | 11 | 0.150 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 16 | 0.150 |
Why?
| | Lymphangiogenesis | 2 | 2018 | 26 | 0.150 |
Why?
| | Germ Cells | 3 | 2024 | 60 | 0.150 |
Why?
| | Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2018 | 12 | 0.150 |
Why?
| | Ipilimumab | 1 | 2018 | 31 | 0.150 |
Why?
| | Tryptophan Oxygenase | 1 | 2018 | 34 | 0.150 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2019 | 64 | 0.150 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 417 | 0.150 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2019 | 113 | 0.150 |
Why?
| | Parenting | 1 | 2022 | 294 | 0.150 |
Why?
| | Cisplatin | 1 | 2020 | 299 | 0.140 |
Why?
| | Vitamin D | 1 | 2021 | 380 | 0.140 |
Why?
| | Area Under Curve | 1 | 2018 | 306 | 0.140 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2018 | 373 | 0.140 |
Why?
| | Tretinoin | 1 | 2018 | 121 | 0.140 |
Why?
| | Immunity, Mucosal | 1 | 2018 | 94 | 0.140 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2019 | 232 | 0.140 |
Why?
| | Global Health | 1 | 2020 | 329 | 0.140 |
Why?
| | Drug Delivery Systems | 2 | 2010 | 337 | 0.140 |
Why?
| | Patient Care Management | 1 | 2017 | 56 | 0.130 |
Why?
| | Tryptophan | 1 | 2018 | 177 | 0.130 |
Why?
| | Socioeconomic Factors | 5 | 2021 | 1214 | 0.130 |
Why?
| | Granulocytes | 1 | 2017 | 77 | 0.130 |
Why?
| | Case-Control Studies | 3 | 2020 | 3384 | 0.130 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2023 | 707 | 0.130 |
Why?
| | Surveys and Questionnaires | 8 | 2024 | 5437 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2001 | 628 | 0.130 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2016 | 71 | 0.130 |
Why?
| | United States | 7 | 2024 | 13913 | 0.130 |
Why?
| | Metaplasia | 1 | 2016 | 57 | 0.130 |
Why?
| | Pancreatic Cyst | 1 | 2017 | 52 | 0.130 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2019 | 431 | 0.130 |
Why?
| | Depression | 3 | 2020 | 1323 | 0.130 |
Why?
| | Genetic Testing | 2 | 2016 | 422 | 0.130 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2015 | 319 | 0.130 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2016 | 34 | 0.130 |
Why?
| | Mammography | 1 | 2017 | 146 | 0.130 |
Why?
| | Lung Neoplasms | 2 | 2021 | 2344 | 0.130 |
Why?
| | Prostatic Neoplasms | 2 | 2021 | 999 | 0.120 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 1995 | 12 | 0.120 |
Why?
| | Cellular Microenvironment | 1 | 2016 | 84 | 0.120 |
Why?
| | Antiparkinson Agents | 1 | 1995 | 28 | 0.120 |
Why?
| | Levodopa | 1 | 1995 | 30 | 0.120 |
Why?
| | Epithelium | 2 | 2015 | 311 | 0.120 |
Why?
| | Transforming Growth Factor beta3 | 1 | 2015 | 9 | 0.120 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 340 | 0.120 |
Why?
| | Chronic Pain | 1 | 2019 | 253 | 0.120 |
Why?
| | Cytophagocytosis | 1 | 2015 | 8 | 0.120 |
Why?
| | Prophylactic Surgical Procedures | 1 | 2015 | 6 | 0.120 |
Why?
| | Adherens Junctions | 1 | 2015 | 25 | 0.120 |
Why?
| | Paracrine Communication | 1 | 2015 | 60 | 0.120 |
Why?
| | Rats | 6 | 2021 | 5487 | 0.120 |
Why?
| | Phosphoproteins | 2 | 2015 | 333 | 0.120 |
Why?
| | Gastrointestinal Microbiome | 1 | 2022 | 641 | 0.120 |
Why?
| | Hodgkin Disease | 1 | 2016 | 133 | 0.120 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 209 | 0.120 |
Why?
| | Menarche | 1 | 2015 | 59 | 0.120 |
Why?
| | Lymphocyte Activation | 3 | 2017 | 1110 | 0.120 |
Why?
| | Pyrimidines | 1 | 2018 | 458 | 0.120 |
Why?
| | Spleen | 1 | 2017 | 508 | 0.120 |
Why?
| | Lymph Node Excision | 2 | 2021 | 164 | 0.110 |
Why?
| | Survivors | 3 | 2023 | 464 | 0.110 |
Why?
| | Microfilament Proteins | 1 | 2015 | 128 | 0.110 |
Why?
| | Survival Analysis | 4 | 2021 | 1271 | 0.110 |
Why?
| | Pregnancy Outcome | 3 | 2023 | 392 | 0.110 |
Why?
| | Retrospective Studies | 9 | 2021 | 14553 | 0.110 |
Why?
| | Extracellular Matrix | 2 | 2016 | 508 | 0.110 |
Why?
| | Genes, BRCA2 | 2 | 2015 | 22 | 0.110 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2014 | 31 | 0.110 |
Why?
| | Amenorrhea | 1 | 2014 | 27 | 0.110 |
Why?
| | Medication Adherence | 1 | 2019 | 561 | 0.110 |
Why?
| | Genes, BRCA1 | 2 | 2015 | 30 | 0.110 |
Why?
| | Odds Ratio | 4 | 2020 | 1022 | 0.110 |
Why?
| | Calcium-Binding Proteins | 1 | 2015 | 213 | 0.110 |
Why?
| | Brain Edema | 1 | 2014 | 61 | 0.110 |
Why?
| | Multivariate Analysis | 2 | 2019 | 1501 | 0.110 |
Why?
| | Collagen | 2 | 2021 | 438 | 0.110 |
Why?
| | Monocytes | 1 | 2017 | 554 | 0.110 |
Why?
| | Spouses | 1 | 2015 | 103 | 0.110 |
Why?
| | Male | 19 | 2022 | 63759 | 0.110 |
Why?
| | Tremor | 1 | 1994 | 60 | 0.110 |
Why?
| | Astrocytes | 1 | 2015 | 197 | 0.110 |
Why?
| | Signal Transduction | 4 | 2020 | 4935 | 0.110 |
Why?
| | Neoplastic Cells, Circulating | 2 | 2016 | 70 | 0.110 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 5085 | 0.100 |
Why?
| | Nitriles | 1 | 2014 | 169 | 0.100 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 3 | 2019 | 59 | 0.100 |
Why?
| | Infertility, Female | 1 | 2014 | 102 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 954 | 0.100 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 925 | 0.100 |
Why?
| | Trans-Activators | 1 | 2015 | 392 | 0.100 |
Why?
| | Triazoles | 1 | 2014 | 148 | 0.100 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2012 | 25 | 0.100 |
Why?
| | Lymphatic Vessels | 3 | 2019 | 61 | 0.100 |
Why?
| | Genome-Wide Association Study | 1 | 2019 | 1326 | 0.100 |
Why?
| | Myeloid Cells | 1 | 2013 | 142 | 0.100 |
Why?
| | Drug Design | 1 | 2013 | 158 | 0.100 |
Why?
| | Mice, Inbred C57BL | 6 | 2019 | 5468 | 0.100 |
Why?
| | Live Birth | 2 | 2023 | 57 | 0.100 |
Why?
| | Logistic Models | 5 | 2016 | 1989 | 0.100 |
Why?
| | Genes, Bacterial | 1 | 2012 | 159 | 0.090 |
Why?
| | Apoptosis | 3 | 2019 | 2489 | 0.090 |
Why?
| | Wound Healing | 1 | 2014 | 308 | 0.090 |
Why?
| | Transcriptome | 2 | 2021 | 875 | 0.090 |
Why?
| | Double-Blind Method | 3 | 2021 | 1877 | 0.090 |
Why?
| | Fibrillar Collagens | 1 | 2011 | 14 | 0.090 |
Why?
| | Interpersonal Relations | 1 | 2015 | 395 | 0.090 |
Why?
| | Treatment Outcome | 7 | 2021 | 10241 | 0.090 |
Why?
| | Progesterone | 1 | 2013 | 245 | 0.090 |
Why?
| | Patient Participation | 1 | 2015 | 414 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 329 | 0.090 |
Why?
| | Membrane Proteins | 2 | 2015 | 1119 | 0.090 |
Why?
| | Antigen Presentation | 2 | 2018 | 207 | 0.090 |
Why?
| | Streptococcus agalactiae | 1 | 2012 | 93 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2020 | 808 | 0.090 |
Why?
| | Biopsy, Needle | 1 | 2011 | 187 | 0.090 |
Why?
| | Adenocarcinoma | 2 | 2015 | 893 | 0.080 |
Why?
| | Estrogen Antagonists | 1 | 2010 | 46 | 0.080 |
Why?
| | Parkinson Disease | 1 | 1995 | 462 | 0.080 |
Why?
| | Sexual Behavior | 1 | 2014 | 481 | 0.080 |
Why?
| | Clinical Trials as Topic | 3 | 2017 | 1005 | 0.080 |
Why?
| | Cell Fusion | 2 | 2006 | 51 | 0.080 |
Why?
| | Pregnancy Trimester, Second | 1 | 2009 | 77 | 0.080 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2021 | 208 | 0.080 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2021 | 108 | 0.080 |
Why?
| | Mucin-1 | 1 | 2009 | 19 | 0.080 |
Why?
| | Cell Movement | 3 | 2019 | 950 | 0.080 |
Why?
| | Reference Standards | 2 | 2012 | 176 | 0.080 |
Why?
| | Interferon beta-1a | 1 | 2008 | 12 | 0.080 |
Why?
| | Drug Monitoring | 1 | 2010 | 216 | 0.080 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2019 | 307 | 0.080 |
Why?
| | Glatiramer Acetate | 1 | 2008 | 18 | 0.080 |
Why?
| | Pregnancy Trimester, First | 1 | 2009 | 137 | 0.080 |
Why?
| | Macrophage Activation | 1 | 2010 | 189 | 0.080 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 182 | 0.070 |
Why?
| | Clinical Trials, Phase I as Topic | 2 | 2020 | 51 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 4 | 2016 | 2403 | 0.070 |
Why?
| | Quinolines | 2 | 2021 | 156 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2018 | 2016 | 0.070 |
Why?
| | Interferon-beta | 1 | 2008 | 89 | 0.070 |
Why?
| | Metalloproteases | 1 | 2008 | 43 | 0.070 |
Why?
| | Sensitivity and Specificity | 3 | 2013 | 1847 | 0.070 |
Why?
| | Aged, 80 and over | 5 | 2020 | 7066 | 0.070 |
Why?
| | Extracellular Matrix Proteins | 1 | 2009 | 144 | 0.070 |
Why?
| | Gonadal Steroid Hormones | 1 | 2009 | 132 | 0.070 |
Why?
| | Age of Onset | 2 | 2021 | 494 | 0.070 |
Why?
| | Genomics | 2 | 2023 | 716 | 0.070 |
Why?
| | Cell Cycle | 2 | 2021 | 583 | 0.070 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2009 | 373 | 0.070 |
Why?
| | Follow-Up Studies | 3 | 2024 | 4896 | 0.070 |
Why?
| | Maximum Tolerated Dose | 2 | 2018 | 193 | 0.070 |
Why?
| | Disease Susceptibility | 1 | 2009 | 334 | 0.070 |
Why?
| | HIV Infections | 1 | 2001 | 2730 | 0.070 |
Why?
| | Antibodies, Monoclonal | 3 | 2009 | 1368 | 0.070 |
Why?
| | ErbB Receptors | 3 | 2017 | 605 | 0.070 |
Why?
| | Gene Knockdown Techniques | 2 | 2020 | 317 | 0.070 |
Why?
| | Sternum | 1 | 2006 | 25 | 0.060 |
Why?
| | Mice, Nude | 3 | 2015 | 680 | 0.060 |
Why?
| | Membrane Glycoproteins | 2 | 2019 | 477 | 0.060 |
Why?
| | Cell Survival | 2 | 2020 | 1086 | 0.060 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 1033 | 0.060 |
Why?
| | Postmenopause | 2 | 2005 | 349 | 0.060 |
Why?
| | Ovariectomy | 2 | 2019 | 137 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2019 | 4102 | 0.060 |
Why?
| | Mammaplasty | 2 | 2021 | 101 | 0.060 |
Why?
| | Administration, Oral | 2 | 2018 | 787 | 0.060 |
Why?
| | Axilla | 2 | 2021 | 46 | 0.060 |
Why?
| | Child | 6 | 2022 | 20962 | 0.060 |
Why?
| | Forkhead Transcription Factors | 2 | 2018 | 184 | 0.060 |
Why?
| | Models, Biological | 2 | 2012 | 1724 | 0.060 |
Why?
| | Infant, Newborn | 2 | 2023 | 5772 | 0.060 |
Why?
| | Fear | 2 | 2021 | 333 | 0.060 |
Why?
| | Dendritic Cells | 2 | 2005 | 481 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2008 | 827 | 0.060 |
Why?
| | Solubility | 1 | 2005 | 232 | 0.060 |
Why?
| | Analysis of Variance | 3 | 2014 | 1291 | 0.060 |
Why?
| | Ovulation Induction | 1 | 2024 | 52 | 0.060 |
Why?
| | Neoplastic Processes | 1 | 2023 | 4 | 0.050 |
Why?
| | Cancer Vaccines | 1 | 2005 | 164 | 0.050 |
Why?
| | Weaning | 2 | 2016 | 48 | 0.050 |
Why?
| | Multiple Myeloma | 1 | 2005 | 125 | 0.050 |
Why?
| | North America | 1 | 2024 | 294 | 0.050 |
Why?
| | Cryopreservation | 1 | 2024 | 94 | 0.050 |
Why?
| | Celecoxib | 2 | 2014 | 39 | 0.050 |
Why?
| | Peptide YY | 1 | 2022 | 13 | 0.050 |
Why?
| | Peptides | 1 | 2008 | 926 | 0.050 |
Why?
| | Ghrelin | 1 | 2022 | 32 | 0.050 |
Why?
| | Withholding Treatment | 1 | 2023 | 71 | 0.050 |
Why?
| | DNA End-Joining Repair | 1 | 2022 | 18 | 0.050 |
Why?
| | Sensation | 1 | 2022 | 51 | 0.050 |
Why?
| | Cost of Illness | 1 | 2024 | 277 | 0.050 |
Why?
| | Appetite | 1 | 2022 | 61 | 0.050 |
Why?
| | Mucins | 1 | 2022 | 70 | 0.050 |
Why?
| | Colorado | 3 | 2020 | 4410 | 0.050 |
Why?
| | Chromosome Aberrations | 1 | 2022 | 140 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2007 | 735 | 0.050 |
Why?
| | Heterozygote | 1 | 2022 | 271 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 336 | 0.050 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2021 | 41 | 0.050 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2015 | 534 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2012 | 3089 | 0.050 |
Why?
| | Genes, p53 | 1 | 2021 | 70 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2021 | 94 | 0.050 |
Why?
| | Hypertrophy | 1 | 2021 | 125 | 0.050 |
Why?
| | In Situ Hybridization | 1 | 2001 | 296 | 0.050 |
Why?
| | Placebos | 1 | 2021 | 201 | 0.050 |
Why?
| | Protective Agents | 1 | 2021 | 39 | 0.040 |
Why?
| | DNA Repair | 1 | 2022 | 210 | 0.040 |
Why?
| | DNA Replication | 1 | 2022 | 225 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2021 | 121 | 0.040 |
Why?
| | Immunity | 1 | 2021 | 138 | 0.040 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2019 | 1058 | 0.040 |
Why?
| | Hormones | 1 | 2021 | 140 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 374 | 0.040 |
Why?
| | Pregnancy Rate | 1 | 2020 | 60 | 0.040 |
Why?
| | Hospitals, University | 1 | 2021 | 180 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2022 | 521 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2021 | 287 | 0.040 |
Why?
| | Arm | 1 | 2021 | 107 | 0.040 |
Why?
| | Flow Cytometry | 3 | 2013 | 1160 | 0.040 |
Why?
| | Kidney Neoplasms | 1 | 2004 | 347 | 0.040 |
Why?
| | Morbidity | 1 | 2021 | 302 | 0.040 |
Why?
| | Consolidation Chemotherapy | 1 | 2019 | 9 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2020 | 318 | 0.040 |
Why?
| | SEER Program | 1 | 2021 | 202 | 0.040 |
Why?
| | Age Distribution | 1 | 2020 | 372 | 0.040 |
Why?
| | Energy Intake | 1 | 2022 | 462 | 0.040 |
Why?
| | Terminology as Topic | 1 | 2021 | 204 | 0.040 |
Why?
| | DNA, Viral | 1 | 2001 | 347 | 0.040 |
Why?
| | Fibronectins | 1 | 2020 | 127 | 0.040 |
Why?
| | Unemployment | 1 | 2019 | 43 | 0.040 |
Why?
| | Vaginal Diseases | 1 | 2019 | 21 | 0.040 |
Why?
| | Base Sequence | 2 | 2016 | 2142 | 0.040 |
Why?
| | Sulfonamides | 2 | 2014 | 497 | 0.040 |
Why?
| | Immunotherapy | 2 | 2014 | 596 | 0.040 |
Why?
| | Leuprolide | 1 | 2019 | 19 | 0.040 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2019 | 65 | 0.040 |
Why?
| | Weight Gain | 1 | 2022 | 510 | 0.040 |
Why?
| | Crosses, Genetic | 1 | 2018 | 134 | 0.040 |
Why?
| | Interleukin-10 | 2 | 2014 | 304 | 0.040 |
Why?
| | Hot Flashes | 1 | 2019 | 82 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2018 | 22 | 0.040 |
Why?
| | Factor Analysis, Statistical | 1 | 2019 | 284 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2019 | 129 | 0.040 |
Why?
| | Integrins | 1 | 2018 | 94 | 0.040 |
Why?
| | Body Weight | 1 | 2022 | 947 | 0.040 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2018 | 91 | 0.040 |
Why?
| | Phenotype | 2 | 2020 | 3062 | 0.040 |
Why?
| | Kynurenine | 1 | 2018 | 113 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2020 | 590 | 0.030 |
Why?
| | Contraceptives, Oral | 1 | 2017 | 38 | 0.030 |
Why?
| | Behavior | 1 | 2018 | 92 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2021 | 639 | 0.030 |
Why?
| | B7-H1 Antigen | 1 | 2019 | 198 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2021 | 532 | 0.030 |
Why?
| | Weight Loss | 1 | 2022 | 740 | 0.030 |
Why?
| | Tumor Escape | 1 | 2017 | 39 | 0.030 |
Why?
| | Educational Status | 1 | 2019 | 474 | 0.030 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 204 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2016 | 43 | 0.030 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2024 | 813 | 0.030 |
Why?
| | Emulsions | 1 | 2016 | 51 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 1042 | 0.030 |
Why?
| | Alleles | 1 | 2019 | 843 | 0.030 |
Why?
| | Risk Assessment | 2 | 2020 | 3269 | 0.030 |
Why?
| | Cell Count | 1 | 2017 | 318 | 0.030 |
Why?
| | Population Surveillance | 1 | 2019 | 439 | 0.030 |
Why?
| | Immune Tolerance | 1 | 2018 | 356 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 251 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1368 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2017 | 310 | 0.030 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2016 | 124 | 0.030 |
Why?
| | Body Mass Index | 2 | 2015 | 2274 | 0.030 |
Why?
| | Antigens, Differentiation | 1 | 2015 | 82 | 0.030 |
Why?
| | Medicare | 1 | 2021 | 719 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 391 | 0.030 |
Why?
| | Biomarkers | 2 | 2021 | 3971 | 0.030 |
Why?
| | Hybrid Cells | 2 | 2005 | 48 | 0.030 |
Why?
| | Directive Counseling | 1 | 2015 | 47 | 0.030 |
Why?
| | Cognition | 1 | 2022 | 1125 | 0.030 |
Why?
| | Reproduction | 1 | 2016 | 198 | 0.030 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2015 | 80 | 0.030 |
Why?
| | Terminal Care | 1 | 2018 | 216 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 304 | 0.030 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 253 | 0.030 |
Why?
| | Genotype | 1 | 2019 | 1829 | 0.030 |
Why?
| | Tumor Burden | 1 | 2015 | 287 | 0.030 |
Why?
| | Leukocyte Common Antigens | 1 | 2014 | 82 | 0.030 |
Why?
| | Dinoprostone | 1 | 2014 | 187 | 0.030 |
Why?
| | Child, Preschool | 2 | 2021 | 10522 | 0.030 |
Why?
| | STAT5 Transcription Factor | 1 | 2013 | 48 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2013 | 53 | 0.030 |
Why?
| | Dermoscopy | 1 | 2013 | 10 | 0.030 |
Why?
| | Wnt Signaling Pathway | 1 | 2015 | 170 | 0.030 |
Why?
| | Massachusetts | 1 | 2014 | 159 | 0.030 |
Why?
| | Necrosis | 1 | 2014 | 234 | 0.030 |
Why?
| | Immunoblotting | 1 | 2014 | 306 | 0.030 |
Why?
| | beta Catenin | 1 | 2015 | 224 | 0.030 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 484 | 0.030 |
Why?
| | Oncogenes | 1 | 2013 | 110 | 0.030 |
Why?
| | Family Health | 1 | 1994 | 198 | 0.030 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2013 | 86 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2018 | 749 | 0.030 |
Why?
| | Karyotyping | 1 | 2012 | 99 | 0.030 |
Why?
| | Immune System | 1 | 2014 | 175 | 0.020 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2014 | 204 | 0.020 |
Why?
| | Adiposity | 1 | 2017 | 504 | 0.020 |
Why?
| | Observer Variation | 1 | 2013 | 314 | 0.020 |
Why?
| | Menopause | 1 | 2015 | 297 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1551 | 0.020 |
Why?
| | Carcinogenesis | 1 | 2013 | 214 | 0.020 |
Why?
| | Cell Division | 1 | 2013 | 790 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 1013 | 0.020 |
Why?
| | Calibration | 1 | 2012 | 140 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 2 | 2015 | 2511 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2018 | 2888 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2062 | 0.020 |
Why?
| | Palliative Care | 1 | 2018 | 706 | 0.020 |
Why?
| | Interferon-gamma | 2 | 2005 | 773 | 0.020 |
Why?
| | RNA, Bacterial | 1 | 2012 | 182 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2739 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2018 | 1900 | 0.020 |
Why?
| | Genome, Human | 1 | 2013 | 393 | 0.020 |
Why?
| | Self Report | 1 | 2015 | 800 | 0.020 |
Why?
| | Photochemotherapy | 1 | 2010 | 32 | 0.020 |
Why?
| | Cell Line | 1 | 2016 | 2780 | 0.020 |
Why?
| | Mice, SCID | 1 | 2011 | 350 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2014 | 870 | 0.020 |
Why?
| | Universities | 1 | 2013 | 409 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2012 | 324 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 1872 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 318 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1242 | 0.020 |
Why?
| | Matrix Metalloproteinases | 1 | 2010 | 91 | 0.020 |
Why?
| | Keratin-19 | 1 | 2009 | 3 | 0.020 |
Why?
| | Immunomagnetic Separation | 1 | 2009 | 3 | 0.020 |
Why?
| | Physician-Patient Relations | 1 | 2014 | 542 | 0.020 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2009 | 20 | 0.020 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2009 | 82 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1434 | 0.020 |
Why?
| | Vinblastine | 1 | 2009 | 70 | 0.020 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2009 | 90 | 0.020 |
Why?
| | Flavonoids | 1 | 2009 | 76 | 0.020 |
Why?
| | Blotting, Western | 1 | 2011 | 1204 | 0.020 |
Why?
| | Species Specificity | 1 | 2010 | 568 | 0.020 |
Why?
| | ADAM12 Protein | 1 | 2008 | 4 | 0.020 |
Why?
| | Perilipin-1 | 1 | 2008 | 17 | 0.020 |
Why?
| | Estrogen Receptor Modulators | 1 | 2008 | 17 | 0.020 |
Why?
| | Sex Factors | 1 | 1994 | 1973 | 0.020 |
Why?
| | S100 Proteins | 1 | 2008 | 35 | 0.020 |
Why?
| | ADAM Proteins | 1 | 2008 | 59 | 0.020 |
Why?
| | Perimenopause | 1 | 2008 | 60 | 0.020 |
Why?
| | Prevalence | 1 | 2014 | 2564 | 0.020 |
Why?
| | DNA Primers | 1 | 2009 | 508 | 0.020 |
Why?
| | Radiotherapy | 1 | 2008 | 185 | 0.020 |
Why?
| | Androstadienes | 1 | 2008 | 106 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2008 | 124 | 0.020 |
Why?
| | Piperidines | 1 | 2009 | 200 | 0.020 |
Why?
| | Gene Expression | 1 | 2012 | 1465 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 515 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2008 | 160 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2008 | 483 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2009 | 844 | 0.020 |
Why?
| | Pleural Effusion | 1 | 2006 | 51 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 756 | 0.020 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2005 | 50 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2005 | 41 | 0.020 |
Why?
| | Receptors, CCR7 | 1 | 2005 | 28 | 0.020 |
Why?
| | Receptors, Chemokine | 1 | 2005 | 45 | 0.010 |
Why?
| | Antigens, CD34 | 1 | 2005 | 88 | 0.010 |
Why?
| | Positron-Emission Tomography | 1 | 2006 | 282 | 0.010 |
Why?
| | Interleukin-12 | 1 | 2005 | 118 | 0.010 |
Why?
| | Hemocyanins | 1 | 2004 | 62 | 0.010 |
Why?
| | Stress, Psychological | 1 | 2012 | 1070 | 0.010 |
Why?
| | Patient Care Planning | 1 | 2005 | 146 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2008 | 741 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2004 | 224 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2006 | 590 | 0.010 |
Why?
| | Cell Separation | 1 | 2004 | 316 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2004 | 931 | 0.010 |
Why?
| | Brain | 1 | 2014 | 2677 | 0.010 |
Why?
| | Paclitaxel | 1 | 2003 | 218 | 0.010 |
Why?
| | Pilot Projects | 1 | 2003 | 1597 | 0.010 |
Why?
| | Vaccination | 1 | 2004 | 1348 | 0.010 |
Why?
|
|
Borges's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|